T regulatory type 1 cells in squamous cell carcinoma of the head and neck: Mechanisms of suppression and expansion in advanced disease

Clinical Cancer Research

Volumn 14, Issue 12, 2008, Pages 3706-3715

  Bergmann, Christoph ^a,c   Strauss, Laura ^a   Wang, Yun ^a   Szczepanski, Miroslaw J ^a   Lang, Stephan ^c   Johnson, Jonas T ^b   Whiteside, Theresa L ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 10 ANTIBODY; INTERLEUKIN 15; INTERLEUKIN 2; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; INTERLEUKIN 2 RECEPTOR ALPHA;

ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SQUAMOUS CELL CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; CANCER STAGING; CASE CONTROL STUDY; CELL ADHESION; CHEMISTRY; CULTURE MEDIUM; DISEASE COURSE; HEAD AND NECK TUMOR; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHYSIOLOGY;

CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CELL ADHESION; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; DISEASE PROGRESSION; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNE TOLERANCE; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASM STAGING; T-LYMPHOCYTES, REGULATORY;

EID: 52449125138     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-5126     Document Type: Article

References (43)

1. Lang S, Wollenberg B, Dellian M, et al. Clinical and epidemiological data of patients with malignomas of the head and neck. Laryngorhinootologie 2002;81:499-508.
2. Forastiere A, Koch W.Trotti A, Sidransky D. Head and neck cancer. N Engl J Med 2001;345:1890-900.
3. Chin D, Boyle GM, Porceddu S,Theile DR, Parsons PG, Coman WB. Head and neck cancer: past, present and future. Expert Rev Anticancer Ther 2006;6:1111-8.
4. Young MR. Protective mechanisms of head and neck squamous cell carcinomas from immune assault. Head Neck 2006;28:462-70.
5. Whiteside TL. Immunobiology of head and neck cancer. Cancer Metastasis Rev 2005;24:95-105.
6. Kawakami Y, Rosenberg SA. Human tumor antigens recognized by T-cells. Immunol Res 1997;16:313-39.
7. Adler AJ. Mechanisms of Tcell tolerance and suppression in cancer mediated by tumor-associated antigens and hormones. Curr Cancer Drug Targets 2007;7:3-14.
8. Gershon RK, Kondo K. Infectious immunological tolerance. Immunology 1971;21:903-14.
9. Sakaguchi S, Sakaguchi N, Asano M, Itoh M.Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-64.
10. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997;389:737-42.
11. Weiner HL. Induction and mechanism of action of transforming growth factor-ß-secreting Th3 regulatory cells. Immunol Rev 2001;182:207-14.
12. + regulatoryTcells and their ligands: implications for immunotherapy. Immunity 2004;20:107-18.
13. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK. lnterleukin-10-secreting typel regulatoryTcells in rodents and humans. Immunol Rev 2006;212:28-50.
14. Saloga J, Bellinghausen I, Knop J. Do Tr1 cells play a role in immunotherapy? Int Arch Allergy Immunol 1999;118:210-11.
15. + T-cell subpopulations in head and neck cancers. Clin Cancer Res 2006;12:465-72.
16. Ichihara F, Kono K.Takahashi A, Kawaida H, Sugai H, Fujii H. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003;9:4404-8.
17. + regulatoryTcells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 2006;12:5423-34.
18. + regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer 2005;92:913-20.
19. Liyanage UK, Goedegebuure PS, Moore TT, et al. Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma. J Immunother 2006;29:416-24.
20. Ling KL, Pratap SE, Bates GJ, et al. Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Cancer Immunol 2007;7:7.
21. + nTreg clones obtained from peripheral blood of normal controls and patients with cancer. Int J Cancer 2007;121:2473-83.
22. + p53 peptide-specific T cells and regulatory T cells at tumor sites. Cancer Immunol Immunother 2005;54:1072-81.
23. 1 mediates suppression in the tumor microen-vironment. Clin Cancer Res 2007;13:4345-54.
24. Bergmann C, Strauss L, Zeidler R, Lang S, Whiteside TL. Expansion of human T regulatory type 1 cells in the microenvironment of COX-2 overexpressing head and neck squamous cell carcinoma. Cancer Res 2007;67:8865-73.
25. Zhou G, Levitsky HI. Natural regulatory T cells and de now-induced regulatory T cells contribute independently to tumor-specific tolerance. J Immunol 2007;178:2155-62.
26. Whiteside TL, Miescher S, MacDonald HR,Von Fliedner V. Separation of tumor-infiltrating lymphocytes from tumor cells in human solid tumors. A comparison between velocity sedimentation and discontinuous density gradients. J Immunol Methods 1986;90:221-33.
27. Bergmann C, Strauss L, Zeidler R, Lang S, Whiteside TL. Expansion and characteristics of human T regulatory type 1 cells in co-cultures simulating tumor micro-environment. Cancer Immunol Immunother 2007;56:1429-42.
28. Kruskal W, Wallis W. Use of ranks in one-criterion variance analysis. J Am Stat Assoc 1952;47:583-21
29. + T cells. J Immunol 2007; 179:1427-30.
30. Kemper C, Atkinson JP.T-cell regulation: with complements from innate immunity. Nat Rev Immunol 2007;7:9-18.
31. + Tcells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007:13:6301-11.
32. Whiteside TL. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 2006;16:3-15.
33. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006;108:804-11.
34. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9.
35. Ferris RL, Whiteside TL, Ferrone S. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res 2006;12:3890-5.
36. Fricke I, Gabrilovich Dl. Dendritic cells and tumor microenvironment: a dangerous liaison. Immunol Invest 2006;35:459-83.
37. + Tregulatory cells: implications and impact on tumor-mediated immune suppression. J Immunol 2008;180:2967-80.
38. Kemper C, Verbsky JW, Price JD, Atkinson JP.T cell stimulation and regulation: with complements from CD46. Immunol Res 2005;32:31-43.
39. Gregori S, Bacchetta R, Passerini L, Levings MK, Roncarolo MG. Isolation, expansion and characterization of human natural and adaptive regulatory T cells Meth Mol Biol 2007;380:83-105.
40. Kryczek I, Wei S, Zou L, et al. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-12 in the tumor microenvironment. J Immunol 2007;178:6730-33.
41. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006;6:24-37.
42. Banerjee DK, Dhodapkar MV, Matayeva E, Steinman RM, Dhodapkar KM. Expansion of FOXP3high regulatoryTcells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood 2006;108:2655-61.
43. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007;117:1167-74.